Bio News

MedPharm has signed an agreement with a global pharmaceutical company to transfer commercial manufacturing and provide manufacturing support for a branded specialty topical drug.
This is MedPharm’s fifth commercial agreement in the past 20 months.
MedPharm expects to generate technology transfer revenue in 2026 and 2027 and commercial manufacturing revenue in 2027.

BIOBOOK TEAM
biobookmedia@biobook.co.krEuropean CHMP Recommends Approval of AstraZeneca’s Blood Pressure Drug Baxpendi
Novo Seeks U.S. and European Approval for Sickle Cell Drug Etavopivat
Rezolute Meets Primary Endpoint in Phase 3 Trial for Tumor Hyperinsulinism; FDA Meeting Ahead
Five Brain Disease Startups Raise $450 Million in a Few Weeks
American Cancer Society Revises Prostate Cancer Screening Guidelines for First Time in 16 Years
Shin Dong-kook Raises Stake in Hanmi Science to 30.18% With Over-the-Counter Purchase of 1.38 Million Shares